financetom
Business
financetom
/
Business
/
Market Chatter: Microsoft, OpenAI Find Evidence DeepSeek Breached Rules in Developing AI Models
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Microsoft, OpenAI Find Evidence DeepSeek Breached Rules in Developing AI Models
Jan 29, 2025 3:51 AM

06:20 AM EST, 01/29/2025 (MT Newswires) -- Microsoft ( MSFT )-backed (MSFT) OpenAI says it has evidence that China's DeepSeek used the San Francisco-based company's AI models to train its offering in a possible infringement of intellectual property, the Financial Times reported Wednesday, citing the ChatGPT maker.

OpenAI says it has evidence that DeepSeek improved its performance using OpenAI large language models, the report said.

Microsoft ( MSFT ) and OpenAI investigated into whether unauthorized OpenAI technology was accessed by a group linked to DeepSeek last year, the report cited a person with knowledge as saying.

President Donald Trump's technology envoy David Sacks told Fox News on Tuesday "there's substantial evidence" DeepSeek "distilled" knowledge from OpenAI models, multiple news outlets reported.

OpenAI and Microsoft ( MSFT ) did not immediately reply to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag
Mar 20, 2024
(Reuters) - Orchard Therapeutics, a unit of Japan's Kyowa Kirin ( KYKOF ), priced its newly approved gene therapy for a rare, life-threatening genetic disease on Wednesday at $4.25 million, making it the most expensive drug in the United States. The therapy was approved on Monday, in a first for children with a rare disorder called metachromatic leukodystrophy (MLD), which...
Boston Scientific Insider Sold Shares Worth $963,930, According to a Recent SEC Filing
Boston Scientific Insider Sold Shares Worth $963,930, According to a Recent SEC Filing
Mar 20, 2024
08:57 AM EDT, 03/20/2024 (MT Newswires) -- Jeffrey B. Mirviss, EVP&Pres, Periph Intervent, on March 18, 2024, sold 14,506 shares in Boston Scientific ( BSX ) for $963,930. Following the Form 4 filing with the SEC, Mirviss has control over a total of 58,098 shares of the company, with 58,098 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/885725/000122520824004316/xslF345X03/doc4.xml Price: 67.84, Change: +0.05,...
Watchdog tells Britain's payments sector to brace itself for intervention
Watchdog tells Britain's payments sector to brace itself for intervention
Mar 20, 2024
LONDON, March 20 (Reuters) - Britain's payments regulator said on Wednesday the sector faces targeted intervention to increase competition and remove barriers to innovation and pockets of market power that leave customers picking up the bill. Financial regulators in Britain face pressure to make it easier for start-ups to enter sectors like payments, a magnet for fintechs, to boost economic...
Update: Boeing Expects up to $4.5 Billion Q1 Cash Outflow, Lowers Monthly Production Target
Update: Boeing Expects up to $4.5 Billion Q1 Cash Outflow, Lowers Monthly Production Target
Mar 20, 2024
08:55 AM EDT, 03/20/2024 (MT Newswires) -- (Updates with comments from Brian West in the first three paragraphs.) Boeing ( BA ) has decided to keep monthly B737 jet production below 38 as the planemaker predicted cash outflow of $4 billion to $4.5 billion in Q1, Chief Financial Officer Brian West said Wednesday in a conference. West said the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved